Bing

Celgene (NASDAQ:CELG) shares were down 3.2% during trading on Monday , Marketbeat.com reports. The company traded as low as $119.53 and last traded at $120.09, with a volume of 3,482,288 shares traded. The stock had previously closed at $124.
sleekmoney.com · 9/1/2015
Of course, every once in a while you can locate a true gem within the biotech sector. I believe one such stock is biotech blue-chip Celgene (NASDAQ: CELG ) . Although Celgene still possesses a handful of the …
The Motley Fool · BySean Williams · 8/26/2015
Celgene
Trade-Ideas LLC identified Celgene ( CELG) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate. In addition to specific proprietary factors, Trade-Ideas identified Celgene as such a ...
The Street · 8/24/2015
More from Bing News
Celgene (NASDAQ:CELG)‘s stock had its “outperform” rating reissued by research analysts at William Blair in a research note issued on Friday, ARN reports. A number of other research analysts also recently …
Ticker Report · 8/28/2015
The firm set a “strong-buy” rating and a $160.00 price target on the biopharmaceutical company’s stock. Raymond James’ target price indicates a potential upside of 38.58% from the company’s current price. Shares of Celgene (NASDAQ:CELG ...
wkrb13.com · 1 day ago
... featured in the blog include the Amgen (AMGN), ARIAD (ARIA), Celgene (CELG), Amicus (FOLD) and Alnylam (ALNY). Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free. Here are highlights ...
Yahoo Finance · 17 hours ago
Celgene’s second-quarter 2015 adjusted earnings and revenues were in line with expectations. The company expects adjusted earnings for 2015 in the range of $4.75–$4.85 per share (excluding stock-based …
Mideast Times · 8/21/2015
Celgene (NASDAQ: CELG) announced that its tender offer to purchase any and all issued and outstanding shares of common stock of Receptos, Inc. (Nasdaq: RCPT) at a price of $232.00 per share, net to the seller in cash, without interest and less required ...
StreetInsider · 8/25/2015
NetEase (NASDAQ:NTES) lost nearly 4% as rebound efforts faded some more. The stock regained its 200-day line Thursday but lost it the next day. Celgene (NASDAQ:CELG) fell almost 3%, wiping out Friday's move and then some. The stock is almost …
Investors Business Daily · ByVincent Mao · 8/30/2015
Celgene Corporation (NASDAQ:CELG) stock, after experiencing some sharp upturns and downturns, has traded down 3% in the past one month alone. Much of Celgene's stock price fluctuation can be attributed to the company's plans to buy out Receptos …
bidnessetc.com · 8/19/2015

Celgene

Company
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. I…
Celgene Corporation is an American biotechnology company that manufactures drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are Thalomid, which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum, as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and Revlimid, for which the company has received FDA and EMA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. Revlimid is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate …
Data from: Wikipedia